Adoptive cellular immunotherapy for the treatment of malignant gliomas Article Conference Paper uri icon

Overview

MeSH Major

  • Astrocytoma
  • Brain Neoplasms
  • Glioblastoma
  • Quinazolines

abstract

  • IL-2 plus autogeneic LAK cells can be safely administered intracavitary to treat high grade primary brain tumors with limited toxicity within the central nervous system. Six out of 28 patients had long-term survival of greater than 2 years post-reoperation plus immunotherapy with 2 patients alive over 8 years. The presence of a marked regional eosinophilia appeared to correlate with increased survival and may be predictive of a biologic and therapeutic response. Regional adoptive immune therapy was well tolerated and should be considered an option for patients with high-grade tumors refractive to standard therapeutic approaches.

publication date

  • July 3, 2001

Research

keywords

  • Conference Paper

Identity

Digital Object Identifier (DOI)

  • 10.1016/S1040-8428(01)00122-6

PubMed ID

  • 11418300

Additional Document Info

start page

  • 31

end page

  • 42

volume

  • 39

number

  • 1-2